Variations in cross-neutralizing reactivity is dependent on mutations on immunogenic epitopes in the spike protein of SARS-CoV-2 variants.

Vaxzevria (ChAdOx1-S recombinant) - University of Oxford, Emergent Biosolutions, Jenner Institute, Barinthus Bio, AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/42409113

Anita Desai; Ashwini M Anand; Chakrakodi N Varun; Gajanan N Sapkal; Muralidharan Kesavan; Nayana Siddalingaiah; Pragya D Yadav; Priti Das

Jul 7, 2026